Lim Rebecca, Ricardo Sharon D, Sievert William
The Ritchie Centre, Hudson Institute of Medical Research, ClaytonVIC, Australia.
Department of Obstetrics and Gynaecology, Monash University, MelbourneVIC, Australia.
Front Pharmacol. 2017 Sep 22;8:633. doi: 10.3389/fphar.2017.00633. eCollection 2017.
The development of tissue fibrosis in the context of a wound-healing response to injury is common to many chronic diseases. Unregulated or persistent fibrogenesis may lead to structural and functional changes in organs that increase the risk of significant morbidity and mortality. We will explore the natural history, epidemiology, and pathogenesis of fibrotic disease affecting the lungs, kidneys, and liver as dysfunction of these organs is responsible for a substantial proportion of global mortality. For many patients with end-stage disease, organ transplantation is the only effective therapy to prolong life. However, not all patients are candidates for the major surgical interventions and life-long immunosuppression required for a successful outcome and donor organs may not be available to meet the clinical need. We will provide an overview of the latest treatment strategies for these conditions and will focus on stem or progenitor cell-based therapies for which there is substantial pre-clinical evidence based on animal models as well as early phase clinical trials of cell-based therapy in man.
在对损伤的伤口愈合反应过程中组织纤维化的发展在许多慢性疾病中都很常见。不受控制或持续的纤维化可能导致器官的结构和功能改变，从而增加严重发病和死亡的风险。由于这些器官功能障碍导致全球相当一部分死亡率，我们将探讨影响肺、肾和肝的纤维化疾病的自然史、流行病学和发病机制。对于许多终末期疾病患者，器官移植是延长生命的唯一有效疗法。然而，并非所有患者都适合进行成功治疗所需的重大手术干预和终身免疫抑制，而且可能没有足够的供体器官来满足临床需求。我们将概述这些病症的最新治疗策略，并将重点关注基于干细胞或祖细胞的疗法，这些疗法在动物模型中有大量临床前证据，并且在人体中也有基于细胞疗法的早期临床试验。
